I agree that this site is using cookies. You can find further informations here.
X
Cerchione, Claudio
351  results:
Search for persons X
?
1

Baseline IgM Amounts Can Identify Patients with Poor Outcom..:

Duminuco, Andrea ; Santuccio, Gabriella ; Chiarenza, Annalisa...
Cancers.  16 (2024)  4 - p. 826 , 2024
Link: https://doi.org/10.3390/..
 
?
2

An overview of prognostic markers in patients with CLL:

Braish, Julie ; Cerchione, Claudio ; Ferrajoli, Alessandra
Frontiers in Oncology.  14 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
3

Targeting DNA2 overcomes metabolic reprogramming in multipl..:

Thongon, Natthakan ; Ma, Feiyang ; Baran, Natalia...
Nature Communications.  15 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
4

Comprehensive analysis of clinical outcomes, infectious com..:

Desantis, Vanessa ; Borrelli, Paola ; Panebianco, Teresa...
Clinical and Experimental Medicine.  24 (2024)  1 - p. , 2024
Link: https://doi.org/10.1007/..
 
?
5

Anemia in patients receiving anticancer treatments: focus o..:

Bozzini, Claudia ; Busti, Fabiana ; Marchi, Giacomo...
Frontiers in Oncology.  14 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
6

Elotuzumab plus pomalidomide and dexamethasone in relapsed/..:

Martino, Enrica Antonia ; Palmieri, Salvatore ; Galli, Monica...
Hematological Oncology.  42 (2024)  4 - p. , 2024
Link: https://doi.org/10.1002/..
 
?
7

Bispecific antibodies for the treatment of relapsed/refract..:

Parrondo, Ricardo D. ; Ailawadhi, Sikander ; Cerchione, Claudio
Frontiers in Oncology.  14 (2024)  - p. , 2024
Link: https://doi.org/10.3389/..
 
?
8

Current Therapeutic Sequencing in Chronic Lymphocytic Leuke..:

Mouhssine, Samir ; Maher, Nawar ; Kogila, Sreekar...
Hematology Reports.  16 (2024)  2 - p. 270-282 , 2024
Link: https://doi.org/10.3390/..
 
?
9

POSTER: MM-602 Role of the Combination of FDG-PET Plus Whol..:

Cerchione, Claudio ; Nappi, Davide ; Marchesini, Matteo...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S222 , 2023
Link: https://doi.org/10.1016/..
 
?
10

P-206 3D in vitro modelling of relapsed/refractory multiple..:

Oriani, Matilde ; Alassi, Nour ; Spadazzi, Chiara...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S148-S149 , 2023
Link: https://doi.org/10.1016/..
 
?
11

P-034 Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD..:

Costa, Luciano ; Bar, Noffar ; Mateos, Maria-Victoria...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S52-S53 , 2023
Link: https://doi.org/10.1016/..
 
?
12

The power of telemedicine to improve CAR-T cell therapy pro..:

Canale, Filippo A. ; Martino, Massimo ; Porto, Gaetana...
Supportive Care in Cancer.  31 (2023)  6 - p. , 2023
Link: https://doi.org/10.1007/..
 
?
13

AML-446 Time to Resolution of Myelosuppression and Associat..:

Fathi, Amir T. ; Smith, B. Douglas ; Angiolillo, Anne...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S302 , 2023
Link: https://doi.org/10.1016/..
 
?
14

P-056 Role the combination of FDG pet plus whole body MRI f..:

Cerchione, Claudio ; Nappi, Davide ; Marchesini, Matteo...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S65-S66 , 2023
Link: https://doi.org/10.1016/..
 
?
15

P953: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MR..:

Cerchione, Claudio ; Nappi, Davide ; Marchesini, Matteo...
HemaSphere.  7 (2023)  S3 - p. e3315114 , 2023
Link: https://doi.org/10.1097/..
 
1-15